Health TrialsbyHealthPanel

Lymphoblastic Leukemia, Acute, Childhood

3

Review clinical trials related to Lymphoblastic Leukemia, Acute, Childhood. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

This is an open-label, multicenter, phase 1b study, which is designed to explore the safety, efficacy and PK of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) marketed in China, in combination with APG-2575 in treating R/R Ph+ALL children, and to preliminarily establish the recommended dose of olverembatinib and APG-2575 for children based on the above results.

Participants needed: 19
Trial details
Phase: Phase 1Age: 1-18Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Aug 26, 2026Locations: 4
Eligibility criteria

Children under 18 years of age on the day of signing the informed consent form,... [+23]

Any AEs (excluding alopecia and pigmentation) that are due to other anti-tumor t... [+8]

Read more
Status: Recruiting

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).

Participants needed: 20
Trial details
Phase: Phase 1Age: 6-65Biological sex: AllType: InterventionalSponsor: National University Hospital, SingaporeUpdated: Sep 14, 2021Locations: 1
Eligibility criteria

Minimum level of pulmonary reserve defined as Grade ≤ 1 dyspnoea and oxygen satu... [+5]

Failure to meet any of the inclusion criteria [+8]

Read more
Status: Recruiting

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).

Participants needed: 40
Trial details
Phase: Phase 1Age: 6-80Biological sex: AllType: InterventionalSponsor: National University Hospital, SingaporeUpdated: Sep 9, 2021Locations: 1
Eligibility criteria

Patients who are unable to tolerate standard chemotherapy due to significant tox... [+7]

Failure to meet any of the inclusion criteria. [+8]

Read more